To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

NCT04671303 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences